Healthcare Industry News: ADVIA Centaur
News Release - January 31, 2007
Bio-Rad and Siemens Medical Solutions Diagnostics Enter Into Joint Marketing Agreement to Offer Products to Optimize Clinical Laboratory Test SystemsHERCULES, CA and TARRYTOWN, NY--(Healthcare Sales & Marketing Network)--Jan 31, 2007 -- Bio-Rad Laboratories, Inc. (AMEX:BIO ) (AMEX:BIO-B ), a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Siemens Medical Solutions Diagnostics, a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., today announced a joint marketing agreement under which Bio-Rad will provide its quality control products and Unity(TM) QC data management solutions for use on Siemens Diagnostics' ADVIA® Chemistry and ADVIA Centaur® Immunoassay Systems. The combination of the quality control products and data management solutions will help ensure Siemens Diagnostics customers of the reliability and precision of their clinical laboratory test systems.
"This is an ideal pairing," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "Customers will not only gain access to a greater breadth of quality control products, but they also will have online access to quality control data provided by thousands of laboratories worldwide for peer group interlaboratory comparison."
"Ensuring the reliability of patient data is crucial to overall laboratory performance," said Anthony Bihl, CEO of Siemens Medical Solutions Diagnostics. "Our agreement with Bio-Rad is an important step in providing our customers with the tools they need to generate the best and most reliable data possible."
Laboratories using Bio-Rad and certain Siemens Diagnostics' controls may submit their quality control data to Bio-Rad's Unity(TM) Interlaboratory Program and use one of Bio-Rad's Unity(TM) product options. The Unity products offer varying levels of QC data management functionality ranging from basic QC data submission and participation in significant worldwide peer groups to advanced QC data management and analysis and reports in real time, providing laboratories with increased confidence in their test systems and proficiency survey outcomes. Siemens Diagnostics Chemistry Systems are part of the ADVIA® family of products. For additional product information, visit www.siemens.com/diagnostics.
Bio-Rad Laboratories, Inc. (AMEX:BIO ) (AMEX:BIO-B ) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of $1.1 billion in 2005. For more information, visit www.bio-rad.com.
About Siemens Medical Solutions
Siemens Medical Solutions of Siemens AG (NYSE:SI ) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics -- such as Diagnostic Products Corporation and Bayer Diagnostics -- mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting www.usa.siemens.com/medical-pressroom.
Various statements made within this press release may constitute "forward-looking statements" for the purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectation.
Source: Bio-Rad Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.